Journal of Clinical Pharmacy and Therapeutics

Cover image for Vol. 41 Issue 3

Edited By: A. Li Wan Po

Impact Factor: 1.668

ISI Journal Citation Reports © Ranking: 2014: 171/255 (Pharmacology & Pharmacy)

Online ISSN: 1365-2710

Recently Published Issues

See all

Recently Published Articles

  1. Subtherapeutic voriconazole concentrations associated with concomitant dexamethasone: case report and review of the literature

    K. L. Wallace, R. L. Filipek, R. M. La Hoz and J. C. Williamson

    Version of Record online: 20 MAY 2016 | DOI: 10.1111/jcpt.12401

    Thumbnail image of graphical abstract

    Subtherapeutic voriconazole concentrations due to an interaction with dexamethasone are not recognized by drug interaction databases. This interaction can have a significant impact on outcomes in patients with invasive fungal infections. The following case report discusses the clinical impact of a drug–drug interaction between dexamethasone and voriconazole and illustrates the time course of removal of the dexamethasone and the effect on voriconazole concentrations.

  2. Evaluation of cephalexin failure rates in morbidly obese patients with cellulitis

    K. R. Kaufman, K. M. Thurber, J. G. O'Meara, D. R. Langworthy and D. T. Kashiwagi

    Version of Record online: 19 MAY 2016 | DOI: 10.1111/jcpt.12402

    Thumbnail image of graphical abstract

    This was a single-centre, retrospective cohort analysis to determine if standard cephalexin dosing (500 mg QID) for management of cellulitis was associated with a difference in treatment failure for morbidly obese vs. non-obese patients. Failure rates were not statistically different, however fewer patients met inclusion and exclusion criteria than planned. Further studies with larger sample sizes and/or prospective design are needed.

  3. Population pharmacokinetics of tacrolimus in Thai kidney transplant patients: comparison with similar data from other populations (pages 310–328)

    S. Vadcharavivad, S. Praisuwan, N. Techawathanawanna, W. Treyaprasert and Y. Avihingsanon

    Version of Record online: 18 MAY 2016 | DOI: 10.1111/jcpt.12396

    Thumbnail image of graphical abstract

    Hemoglobin and duration of tacrolimus therapy could partly explain the interindividual variability of tacrolimus pharmacokinetics. A summary review of population pharmacokinetic models of twice daily tacrolimus in adult kidney transplant recipients is also provided.

  4. Dipeptidyl peptidase-IV inhibitors induced bullous pemphigoid: a case report and analysis of cases reported in the European pharmacovigilance database (pages 368–370)

    M. García, M. A. Aranburu, I. Palacios-Zabalza, U. Lertxundi and C. Aguirre

    Version of Record online: 18 MAY 2016 | DOI: 10.1111/jcpt.12397

    Thumbnail image of graphical abstract

    Bullous pemphigoid has been associated with gliptins. We describe a case and analyse all cases of bullous pemphigoid recorded in the European pharmacovigilance database, EudraVigilance (table ). The findings show a disproportionality for bullous pemphigoid and gliptins, except alogliptin (table ) and extend the evidence associating gliptins with this condition.

  5. Safety of antitumour necrosis factor treatments in chronic rheumatic diseases: therapy discontinuations related to side effects (pages 306–309)

    H. Varela, E. Villamañán, C. Plasencia, J. A. Romero, M. Ruano, A. Balsa and A. Herrero

    Version of Record online: 18 MAY 2016 | DOI: 10.1111/jcpt.12393

    Thumbnail image of graphical abstract

    Probability of treatment termination due to an adverse effect in terms of anti-TNF drug administered.